Monday, 26 August 2019
Latest news
Main » Flexion Therapeutics Inc (FLXN) Receives Average Recommendation of "Buy" from Analysts

Flexion Therapeutics Inc (FLXN) Receives Average Recommendation of "Buy" from Analysts

24 March 2017

At the movement Flexion Therapeutics, Inc.

Sanofi has been deal-shopping as its diabetes franchise slows, eyeing companies with price tags in the bolt-on range-as Flexion would be-as well as bigger targets.

At time of reporting this, Flexion shares jumped 40.5 percent. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. "Whether investors see it that way, given thecurrent market uncertainty, will remain to be seen".

More news: SpaceX Launch Schedule 2017: What Next For Elon Musk Company

A number of other brokerages have also recently weighed in on FLXN.

Analysts await Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings on May, 11. Flexion stock has traded below 25 since September 2015. If the two companies joined forces, they would own a considerable market share of the industry. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 11.00% since August 16, 2016 and is uptrending. The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.67 on scale of 1-5.

Flexion Therapeutics (NASDAQ:FLXN) opened at 20.26 on Wednesday. While the company's share hit the 52 week high on Mar 23, 2017 stationing the value of $28.2. The firm's market capitalization is $642.87 million. The company has a 50-day moving average of $19.73 and a 200-day moving average of $18.95. $163,807 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) was bought by COLELLA SAMUEL D on Thursday, December 1.

More news: Female Indian Techie, Son Brutally Murdered In The US

Earnings estimate: "9" Analysts are saying that the company to report next quarterly earnings of $-0.78 per share for period Quarter Ending_Jun-17.

Currently, EPS of Flexion Therapeutics, Inc. The stock grabbed 21 new institutional investments totaling 728,131 shares while 9 institutional investors sold out their entire positions totaling 125,232 shares. The average volume stands around 0.26 million shares. Following the transaction, the insider now owns 65,937 shares of the company's stock, valued at approximately $1,217,197.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. About 4.12 million shares traded or 1374.37% up from the average.

Institutional investors now hold around $450 million or 99.4% in FLXN stock. JPMorgan Chase & Co. boosted its stake in shares of Flexion Therapeutics by 6.3% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 52,850 shares of the specialty pharmaceutical company's stock valued at $1,005,000 after buying an additional 450 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Flexion Therapeutics during the third quarter valued at approximately $402,000. Ltd. acquired a new position in Flexion Therapeutics during the third quarter valued at $620,000.

More news: Under pressure from Sony, nervous Kapil Sharma reaches out to Sunil Grover

Flexion Therapeutics, a United States specialty pharmaceutical company. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Flexion Therapeutics Inc (FLXN) Receives Average Recommendation of